Inclusion Criteria:
* Healthy male or female participant aged 18 years or older.
* Body weight at least 50 kg for males or at least 45 kg for females, with body mass index from 19.0 to 26.0 kg/m2, inclusive.
* No plan for conception or gamete donation and willing to use effective contraception from screening (from 2 weeks before screening for females) until 6 months after the last dose.
* Creatinine clearance greater than 80 mL/min.
* Prothrombin time and activated partial thromboplastin time within the normal ranges.
* Voluntarily provided written informed consent and understood the study procedures.
* Able to comply with and complete the study requirements.
Exclusion Criteria:
* Specific allergy history, current allergic disease, allergic constitution, or known hypersensitivity to rivaroxaban, related compounds, or formulation components.
* Clinically significant abnormal findings on physical examination, vital signs, electrocardiogram, or clinical laboratory testing.
* Clinically significant neurologic, cardiovascular, renal, hepatic, gastrointestinal, respiratory, metabolic, musculoskeletal, or other disease that could affect drug absorption, distribution, metabolism, or excretion.
* Active pathological bleeding, coagulation abnormality, or clinically relevant bleeding risk.
* Positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, or syphilis antibody.
* Hereditary lactose or galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
* Positive pregnancy test or breastfeeding.
* History of drug abuse within 5 years or positive urine drug screen.
* Hospitalization or surgery within 3 months before screening.
* Regular alcohol intake exceeding 14 units per week within 3 months or positive breath alcohol test.
* Smoking more than 5 cigarettes per day on average within 3 months.
* Participation in another clinical study with study drug exposure within 3 months.
* Blood donation or blood loss of at least 400 mL within 3 months, or donation of 2 therapeutic units of platelets within 1 month.
* Use of prescription medication within 14 days, or nonprescription medication, herbal medicine, or health products within 7 days before dosing.
* Use within 28 days before first dosing of drugs that strongly inhibit or induce P-glycoprotein or CYP3A4.
* Consumption within 48 hours before dosing of grapefruit or related products, alcohol-, caffeine-, or xanthine-containing foods or beverages; strenuous exercise; or other factors potentially affecting pharmacokinetics.
* Intolerance of venipuncture or history of needle or blood phobia.
* Special dietary requirements or inability to comply with the standardized diet and study restrictions.
* Any other condition that could prevent completion of the study or that the investigator considered unsuitable for participation.
